Fosun Pharma Gets NMPA Approval for Two Drug Applications, Covering Diabetes and Childhood Constipation
On August 3, 2026, Fosun Pharma announced that its controlling subsidiary Fosun Wanbang (Jiangsu) Pharmaceutical Group received NMPA approval for empagliflozin and metformin hydrochloride extended-release tablets (III). The approved indication is to improve glycemic control in adults with type 2 diabetes already treated with these two drugs, in combination with diet and exercise. Another controlling subsidiary, Suzhou Erye Pharmaceutical, received approval for compound polyethylene glycol (3350) electrolyte powder to treat chronic constipation in children aged 1-11 and fecal impaction in children aged 5-11.
On August 3, 2026, Fosun Pharma announced that the drug registration application for empagliflozin and metformin hydrochloride extended-release tablets (III) from its controlling subsidiary Fosun Wanbang (Jiangsu) Pharmaceutical Group Co. , Ltd. had been approved by the National Medical Products Administration (NMPA). The approved indication is for use in conjunction with diet and exercise in adult patients with type 2 diabetes who are currently receiving empagliflozin and metformin hydrochloride, to improve glycemic control.
A drug registration application from another controlling subsidiary, Suzhou Erye Pharmaceutical Co. , for compound polyethylene glycol (3350) electrolyte powder was also approved by the NMPA. The approved indications are for the treatment of chronic constipation in children aged 1 to 11 years, and for the treatment of fecal impaction in children aged 5 to 11 years, defined as intractable constipation with accumulation of feces in the rectum and/or colon.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Pharmaceuticals, with intensity 30/100 and 80% confidence over a short term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.